ReviewFrontiers in pharmacology2026
Mesenchymal stem cell-derived exosomes in myocardial infarction repair: therapeutic potential and scaffold-based delivery strategies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomaterial-Assisted Stem Cell Therapy and Exosome Delivery in Myocardial Infarction: A Narrative Review.Biomimetics (Basel, Switzerland) · 2026Review
- Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.Frontiers in cell and developmental biology · 2026Review
- A Nanomedicine Strategy: Spatiotemporally Programmed Delivery of Engineered Exosomes via Smart Scaffolds for Craniofacial Bone Regeneration.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) remains a leading cause of global mortality, with current therapeutic modalities offering limited capacity for complete myocardial tissue regeneration. Advances in regenerative medicine have introduced stem cell-based approaches, among which mesenchymal stem cells (MSCs) have garnered significant scientific curiosity due to their multipotent differentiation potential and favorable safety profile. However, evidence suggests that the primary therapeutic effects of MSCs are mediated through their paracrine secretion of bioactive factors, notably exosomes. These MSC-derived exosomes (MSC-Exos) can modulate key aspects of cardiac repair, such as enhancing angiogenesis, preventing apoptosis, and alleviating inflammation by transferring genetic material such as miRNAs, proteins, and lipids and by activating molecular pathways critical to cardiac repair. Numerous studies as well as preclinical and clinical trials are currently investigating MSC-Exos for tissue regeneration. This review critically examines the biological characteristics and underlying mechanisms of MSC-Exos in myocardial repair, with particular focus on cell sources such as bone marrow-derived MSCs (BMMSCs), adipose-derived MSCs (ADSCs), and human umbilical cord MSCs (HUCMSCs), and evaluates their roles from multiple perspectives. Moreover, this review emphasizes innovative delivery approaches, including hydrogel-based systems, aimed at maximizing therapeutic effectiveness and accelerating translational potential. The integration of scaffold technologies and exosome engineering holds substantial promise for translating this cell-free approach into effective clinical treatments, presenting MSC-Exos as a transformative strategy with the potential to markedly improve outcomes in MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.